AzTrials
AzTrials

Brain TumorsREHABrainNCT05192447

The Cognitive-Behavioral Dysfunctions and the Potential of Neuroplasticity in Brain Tumors Patients During Radiotherapy

A study testing Exercise treatment in people with Brain Tumors and Radiotherapy, run by The Greater Poland Cancer Centre at 1 site in Poland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Primary and secondary brain tumors are a constant challenge for the medicine. Tissue sensitivity to ionizing radiation differs and depends on numerous factors and the same dose of radiation may produce different effects in particular structures of the CNS. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Brain Tumors, Radiotherapy
What is being tested?
Exercise treatment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 sitePoland
Study dates
1 Apr 2021to 31 Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with three different CNS groups of tumors: from III and IV brain tumor groups, and metastatic tumors enrolled to RT,
  • Age between 18-70 years,
  • good general health conditions (according to Eastern Cooperative Oncology Group (ECOG) 0-2),
  • obtaining informed consent for participation in the study.

Who cannot join

  • Patients with numerous tumors (above two),
  • psychological or psychiatric illnesses treated pharmacologically,
  • neurological disorders (e.g. MS, Parkinson's disease, meningitis, etc.),
  • significant clinical circulatory failure (above III NYHA).

Trial locations and contacts

1 site in 1 country.

Katarzyna Hojan, MD, PhD contact

+48601509967

katarzyna.hojan@wco.pl

Ewa Tańska, PhD contact

+48618850767

ewa.tanska@wco.pl

Poland1 site, 1 recruiting
  • Greater Poland Cancer Centre

    Poznan, Greater Poland Voivodeship, 61-866

    Katarzyna Hojan, MD, PhD, +48601509967, katarzyna.hojan@wco.pl

    Ewa Tańska, PhD, +48618850767, clinicaltrials@wco.pl

    Recruiting

Other trials in Poland

About this study

Official title: Analysis of the Cognitive-behavioral Dysfunctions Profile and the Potential of Neuroplasticity in Patients With Brain Tumors Subjected to Selected Radiotherapy Techniques and the Possibility of Their Compensation by Psycho-physical Training

Primary and secondary brain tumors are a constant challenge for the medicine. Tissue sensitivity to ionizing radiation differs and depends on numerous factors and the same dose of radiation may produce different effects in particular structures of the CNS. It can also affect the surrounding healthy tissues and lead to adverse effects like the cognitive or physical function impairment. One of brain structures most sensitive to ionizing radiation is the limbic system, especially the hippocampus, because it is here that the postnatal neurogenesis takes place via neural stem cells, which are a self-renewing population of precursor cells. There have been no studies that would thoroughly examine the impact of different CNS radiation therapy techniques on the cognitive function, potential neuroplasticity markers or blood-brain barrier damage in brain tumor patients with a concomitant use of neurocognitive combination therapies or physical exercise, and their impact on the CNS function.

The aim of the study is to assess the impact of selected RT techniques: IMRT, WBRT, and CyberKnife (SRS) on the processes regulating cognitive and physical function in patients with primary (Group III and IV, WHO, 2016) and metastatic CNS tumors. The secondary objective is the analysis of the effect of selected forms of neurorehabilitation on the parameters studied. The study will be a prospective clinical trial conducted in 150 patients. Patient evaluation will be carried out before RT, after RT, during a follow-up visit-3 months after RT, and finally after 6 months. The methods will be used: analysis of the blood-brain barrier permeability markers including exact connection proteins, markers confirming neuroplasticity of the brain, cerebral secretory activity, and onco- and anti-neuronal antibody activity, brain structure analysis (MRI) and volume testing of selected brain structures, and assessment of cognitive and physical function of the patients. The study will be a part of the search trend aiming to explain the mechanism of the formation of cognitive-behavioral disorders in humans based on the most fundamental principles governing information processing in CNS, and the impact of neoplasia and ionizing radiation on selected brain structures and functions. The results of the study might become a starting point for the formulation of new guidelines on the level of physical activity or cognitive exercise in patients treated with CNS radiation therapy.

Read the detailed description

Every year, thousands of patients worldwide undergo radiotherapy (RT) for primary brain tumors (BT) and brain metastases originating from extracranial tumors. Radiation injury is multifactorial and is characterized by e.g. vascular abnormalities, inflammation, gliosis, demyelination, and often at high doses, white matter necrosis. Standard treatment of BT includes high dose megavoltage radiation to the cranial vault, but 50-90% of overall survivors exhibit impaired cognition and functional dysfunction. The radiation cognitive syndrome is still poorly understood, and there is no effective prevention or long-term treatment. Therefore, the investigators will analyze specific molecular markers which may have a relationship with morfological changes in the brain, its secretive and imunological role as well as cognitive function and postulate that previously undetected and comparatively subtle early manifestations of irradiation damage to CNS may synergize over time to form macro- and microstructural abnormalities. The investigators plan to corroborate a hypothesis that impairment of cognitive and motor functions in patients undergoing RT can be limited. In study, the investigators will quantitatively and objectively evaluate the effects of exercise on brain activity during cognitive and physical training in BT patients treated with RT. Therefore, specific objectives include: 1. Analysis of the molecular mechanism in BBB disruption. 2. Multidimensional analysis of specific neuroplasticity markers, onconeural-antibodies etc. 3. Assessment of the volume of the brain structures and their morphology. 4. Analysis of the results of neurocognitive and functional tests.

Significance of the project The Response Assessment in Neuro-Oncology working group recommended that neurocognitive outcome should be considered one of the primary endpoints in BT clinical trials. Despite the importance and clear concern about radiation-induced cognitive decline, the pathophysiology driving the progression of this syndrome remains poorly understood, and there are no effective preventative measures or long-term treatments. To date, there has been no study comparing different techniques of irradiation, namely intensity-modulated photon RT (IMRT), whole brain RT (WBRT), and stereotactic radiosurgery (CyberKnife), in BT patients in the aspect of pathophysiology of BBB or immunological aspects, as well as neurogenesis, neuroplasticity. These methods will be rely on a detailed understanding of radiation dose-volume effects, which link the incidence and severity of neurocognitive and functional impairment to specific volumes and morphology of normal brain. Possible explanations for the preservation of cognition and behavior include the resiliency of the cerebellum, frontal and tempo-parietal lobes, the hippocampus-mammillary complex and other supratentorial regions. Radiation is now known to suppress the proliferation of progenitor cells and their differentiation into neurons. The relatively recent discovery of neural stem cells in discrete areas of the brain is the impetus behind the most recent potential target for radiation. Early changes below the gross anatomical level, including a decline in neurogenesis, microvascular damage, subtle loss of white matter integrity, and disturbances of neuronal morphophysiology, may interact and progressively alter neuronal stem cell niches to impede neuronal function, viability, and progenitor cell differentiation. Therefore, the investigators will thoroughly observe the mechanism of neurogenesis and the possible improvement of neuroprotection and neuroregeneration in BT patients undergoing various forms of RT. Previous research has shown that physical exercise in healthy people is associated with increased structural and functional integrity in regions that overlap with brain functions, including the frontal, motor cortex, and the cerebellum. The precise neurobiological mechanism for cognitive effects of rehabilitation remains unknown, however a vast rodent literature supports a central role of protective neurotrophins, which have been shown to facilitate production of new neurons in the hippocampus, promote synaptic plasticity in cerebral cortex, and enhance growth and protection of neurovasculature and suggests exercise may promote formation and strengthening of connections between the hippocampus and its widespread cortical connections, which improve cognitive and behaviour functioning. However, the specific brain structure and function regions activated during rehabilitation exercise in patients with BT during oncological treatment still remain largely undefined. The study results obtained in this project will provide new knowledge about metabolic and structural pathways of the CNS in the context of RT and will also provide the basis for the development of regenerative medicine in oncology.

Work plan The investigators will conduct study in the Greater Poland Cancer Centre. The participants will be enrolled in this study according study criteria from the Department of Radiotherapy after medical assessment by an oncologist (physician). Evaluation of the all subjects will be carried out: at baseline (T0), one month after RT (T1), and control (T2) - 3 months after RT and final (T3) - 6 months after RT (unless there is a deterioration of health making the assessment impossible, or death). The investigators will monitor the patients by:

  1. Analysis of the patient's blood serum: 1/ markers of BBB disruption: S-100β and circulating tight junction-related proteins (occludin, claudin-5, zonula occludens-1); 2/ factors with potential effect on neuroplasticity - immune-cell production of neurotrophins e.g. brain-derived neurotrophic factor, beta-nerve growth factor, neurotrophin-3, neurotrophin-4/5; 3/ activity of carnosinase and its isoenzymes; 4/ onconeural antibodies (anti-Hu, anti-Ri, anti-Yo, anti-Ma/Ta, anti-Cv2, and anti-amphiphysin as well as anti-myelin, anti-MAG, anti-GAD) and anti-surface neuronal antigens (anti-NMDA, anti-AMPA, anti-GABA, anti-DPPX, anti-LGI1, anti-CASPR) to investigate correlations with types of BT, RT, and possible paraneoplastic syndromes or cognitive impairment.
  2. Assessment of brain structures and volume testing of selected brain structures.
  3. Cognitive and functional assessment using clinical tests. All participants groups treated with different RT techniques (three groups) will by randomly divided to two subgroups: exercise subgroup - EG (these are the patients who will have regular cognitive and physical training) and second subgroup (control group - CG).

Analysis of risk in planned study will be connected with failure to reach targeted number of patients (the investigators will enlarge the recruitment pool across additionally cancer hospitals) or increase dropout rate (motivational information will be provided to participants and clinicians). The Greater Poland Cancer Centre has very modern research infrastructure allowing for execution of the proposed project.

Methods of research The study protocol was accepted by the Ethics Committee of Poznan University of Medical Sciences (No. 703/18), and each recruited participant will be given a written informed consent. The investigators will enroll patients with BT using the updated 2016 edition of the World Health Organization Classification of Tumors of CNS which uses molecular parameters and the histology to define the main tumor categories for the first time. The investigators will analyze 150 patients together with three different CNS groups of tumors: from III and IV brain tumor groups, and metastatic tumors. The study will include patients with BT enrolled to RT, between 18-70 y o , in good general health conditions (according to Eastern Cooperative Oncology Group 0-2), after obtaining informed consent for participation in the study. The investigators are planning to exclude patients with numerous tumors (> 2), with psychological or psychiatric illnesses treated pharmacologically, or with other neurological disorders (e.g. sclerosis multiplex, Parkinson's disease, meningitis, etc.), or significant clinical circulatory failure (> III NYHA). Enrolled patients will be treated with the one of three RT techniques in the Department of Radiotherapy: 1) CyberKnife, which relies on precise 3D imaging and localization to deliver ablative doses of radiation to the tumor, and can significantly reduce exposure of healthy brain tissue (18 Gy per dose to total 66 Gy) or 2) IMRT using conventional fractionation of 1.8 Gy per day to total dose 54 Gy or 2 Gy per dose to the total dose 60 Gy) or 3) WBRT as the treatment choice for metastatic tumors - the fractionation schedule used is 30 Gy delivered in 10 fractions or 20 Gy in 5 days. Participants randomly selected to EG will perform cognitive and physical training (120 min./5 times per week during study observation) conducted by rehabilitation staff who will be employed for this project: physiotherapist and neuropsychologist. For neuropsychological rehabilitation, the investigators will use the RehaCom system - a special neurocognitive programs and software. During RT, EG will do physical training (such as cycling, running on properly calibrated equipment as well as neuromuscular reeducation exercises using advanced technical tool - Neuroforma computer software) with maximum heart rate to 70%HRmax. After RT, participants in EG will do special exercise training at home under supervision of the hospital staff. Participants from CG will be provided with normal hospital care during RT and next will conduct a normal daily activity at home. According to the study evaluation plan, all participants will be observed before and after end of RT, and during control visits (T2, T3) at cancer center. Patients' blood samples will be collected in the Laboratory Ward in the morning, before breakfast according to the study plan. The investigators will evaluate individual markers in the Department of Radiobiology in collaboration from the Department of Neurochemistry and Neuropathology at Poznan University of Medical Sciences, because the Radiobiology Laboratory is fully equipped with all specialized, high-tech instruments required for the execution of this project.. In the Department of Rehabilitation in cancer center, all study participants will be evaluated in terms of cognitive and physical functioning. Raw cognitive test scores will be compared with published normative values according to age and to education. The investigators will include in the study evaluation with the use of Mini-Mental State Examination (MMSE), Benton Visual Retention Test (BVRT), California Verbal Learning Test (CVLT), Color trials test (CTT), Wisconsin Card Sorting Test (WCST), Trail Making Test A and B (TMT A \& B), Montreal Cognitive Assessment (MoCA) 7.2 scale, and Addenbrooke's Cognitive Examination III (ACE III) test as well as the Psychology Experiment Building Language (PEBL) software for objective evaluation of selected cognitive and behavior functions. For general assessment of physical, psychological and social function the investigators will use the Functional Independence Measures (FIM) scale. This will be an unprecedented study yielding unique results on neuroscience in the process of cancer treatment with modern techniques.

Being tested
Exercise treatment
Keywords
neuroplasticity, rehabilitation
Medical subject headings
Brain Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise treatmentBehavioural

    Also called Rehabilitation treatment

    Patients selected to EG will carry out complementary cognitive and physical training under supervision of rehabilitation staff. For neuropsychological exercises, the investigators will use the RehaCom system - high quality scientific neurocognitive disorder therapy programs and software. (Time: 30 min./5 times/week per patient during RT). In this time, EG patients will do physical training (such as cycling, running on properly calibrated equipment for the circulatory system parameter measurement (1hour/ 5 days/ week), and neuromuscular and cognitive reeducation exercises using a technically advanced tool - Neuroforma computer software - 30 min/ 5 times/ week). After the end of RT, patients in EG will do a special exercise training at home under supervision of staff from the Department of Rehabilitation, and cognitive training using special tasks (3 times an hour/per week) at home, and two times/week using RehaCom and Neuroforma (60 min/sesion) in our cancer ceter.

Study groups in NCT05192447
Study groupRoleWhat they receive
Intervention Group = Exercise GroupExperimentalEG will perform complementary cognitive and physical training (120 min./5/per week during study observation)
Receives: Behavioral: Exercise treatment
Control GroupNo interventionCG will be provided with normal hospital care during RT and next will conduct a normal daily activity at home.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Markers of BBB disruption

    The astrocytic protein S-100β will be estimated using enzyme-linked immunoassay (ELISA).

    Measured: up to 48 months

  2. Circulating tight junction-related proteins

    To estimate circulating tight junction-related proteins (OCLN, CLDN5, ZO-1) concentrations, rabbit anti - human OCLN antibodies will be used.

    Measured: up to 48 months

  3. Onkoneural antibodies in blood

    Onconeural antibodies will be identified with indirect immunofluorescence and confirmed with Line blott with the use of recombinants.

    Measured: up to 48 months

Secondary outcomes (3)
  1. Anti-neural antibodies in blood

    Anti-neural antibodies will be tested by means of indirect immunofluorescence only.

    Measured: up to 48 months

  2. Superficial anti-neuronal antibodies in blood

    Superficial anti-neuronal antibodies will be identified in patients' serum by means of cell-based assay.

    Measured: up to 48 months

  3. MRI scans and the selected structures of the brain

    The investigators will assess volumetry and morphology of selected brain structures from MRI scans. Hippocampus, thalamus, cerebellum, brainstem, frontal and tempo-parietal lobes, and total brain volume will be determined from the T1-weighted MRI with FreeSurfer, an automated segmentation tool.

    Measured: up to 48 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jan 2022
  2. Study start1 Apr 2021
  3. Primary completion31 Mar 2025 (estimated)
  4. Study completion31 Mar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05192447
Sponsor's protocol ID
2020/37/B/NZ7/01122
Other IDs
480821
Acronym
REHABrain
Status last verified
Dec 2023
First submitted
29 Jun 2021
Last updated
3 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Attia A, Page BR, Lesser GJ, Chan M. Treatment of radiation-induced cognitive decline. Curr Treat Options Oncol. 2014 Dec;15(4):539-50. doi: 10.1007/s11864-014-0307-3.

    PubMed 25228143
  • Baillieux H, De Smet HJ, Paquier PF, De Deyn PP, Marien P. Cerebellar neurocognition: insights into the bottom of the brain. Clin Neurol Neurosurg. 2008 Sep;110(8):763-73. doi: 10.1016/j.clineuro.2008.05.013. Epub 2008 Jul 7.

    PubMed 18602745
  • Benraiss A, Chmielnicki E, Lerner K, Roh D, Goldman SA. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci. 2001 Sep 1;21(17):6718-31. doi: 10.1523/JNEUROSCI.21-17-06718.2001.

    PubMed 11517261
  • Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stocklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009 Sep;26(9):1497-1507. doi: 10.1089/neu.2008.0738.

    PubMed 19257803
  • Fischl B. FreeSurfer. Neuroimage. 2012 Aug 15;62(2):774-81. doi: 10.1016/j.neuroimage.2012.01.021. Epub 2012 Jan 10.

    PubMed 22248573
  • Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. Clin Cancer Res. 2013 May 1;19(9):2294-300. doi: 10.1158/1078-0432.CCR-11-2903. Epub 2013 Feb 6.

    PubMed 23388505
  • Hipkiss AR, Cartwright SP, Bromley C, Gross SR, Bill RM. Carnosine: can understanding its actions on energy metabolism and protein homeostasis inform its therapeutic potential? Chem Cent J. 2013 Feb 25;7(1):38. doi: 10.1186/1752-153X-7-38.

    PubMed 23442334
  • Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer. 2003 Jun 1;97(11):2806-13. doi: 10.1002/cncr.11409.

    PubMed 12767094
  • Louis DN, et al. (2016) WHO classification of tumours of the central nervous system, ed 4 Lyon, IARC Press

  • Manda K, Ueno M, Anzai K. Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: attenuation by melatonin pretreatment. J Pineal Res. 2009 Jan;46(1):71-8. doi: 10.1111/j.1600-079X.2008.00632.x. Epub 2008 Sep 16.

    PubMed 18798786
  • McDuff SG, Taich ZJ, Lawson JD, Sanghvi P, Wong ET, Barker FG 2nd, Hochberg FH, Loeffler JS, Warnke PC, Murphy KT, Mundt AJ, Carter BS, McDonald CR, Chen CC. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1384-91. doi: 10.1136/jnnp-2013-305166. Epub 2013 May 28.

    PubMed 23715918
  • Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011 May 26;70(4):687-702. doi: 10.1016/j.neuron.2011.05.001.

    PubMed 21609825
  • Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 2003 Jul 15;63(14):4021-7.

    PubMed 12874001
  • Schulzke JD, Fromm M. Tight junctions: molecular structure meets function. Ann N Y Acad Sci. 2009 May;1165:1-6. doi: 10.1111/j.1749-6632.2009.04925.x.

    PubMed 19538280
  • Sun YX, Chu GL (2010) Expression changes of tight junction proteins ZO-1 and occludin after hypoxic-ischemic brain damage in neonatal rats. Zhongguo Xiandai Yixue Zazhi. 20(21):3210-3213

Questions about this trial

What is this clinical trial studying?

A study testing Exercise treatment in people with Brain Tumors and Radiotherapy, run by The Greater Poland Cancer Centre at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Katarzyna Hojan, MD, PhD (+48601509967, katarzyna.hojan@wco.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Markers of BBB disruption (time frame: up to 48 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05192447, which also lists 18 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in